Innate immunity

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Turvey, Stuart E ^a   Broide, David H ^b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Host defense; innate immunity; nucleotide oligomerization domain like receptors; Toll like receptors

Indexed keywords

PHOSPHORYL LIPID A; PLACEBO; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ARTICLE; COMPLEMENT SYSTEM; GENETIC POLYMORPHISM; HEALTH; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAGWEED; SCIENCE;

ADAPTIVE IMMUNITY; ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFECTION; INFECTION CONTROL; NOD SIGNALING ADAPTOR PROTEINS; POLYMORPHISM, GENETIC; TH2 CELLS; TOLL-LIKE RECEPTORS; VACCINES;

EID: 76749091377     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.07.016     Document Type: Article

References (53)

1. Frank M.M. Complement disorders and hereditary angioedema. J Allergy Clin Immunol 125 (2010) S262-S271
2. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
3. Pancer Z., and Cooper M.D. The evolution of adaptive immunity. Annu Rev Immunol 24 (2006) 497-518
4. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
5. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 (2007) 39-45
6. Beutler B. Innate immunity: an overview. Mol Immunol 40 (2004) 845-859
7. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 (1989) 1-13
8. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81 (2007) 1-5
9. Joncker N.T., and Raulet D.H. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 224 (2008) 85-97
10. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., and Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996) 973-983
11. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
12. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
13. Ho J., Li Y., Hirschfeld A.F., Mansouri D., and Turvey S.E. Advances in innate immunity: the role of Toll-like receptor signaling in human disease. J Respir Dis Thorac Surg Intensive Care Tuberc 3 (2004) 7-14
14. Turvey S.E., and Hawn T.R. Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin Immunol 120 (2006) 1-9
15. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 (2003) 2076-2079
16. von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321 (2008) 691-696
17. Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., et al. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23 (2005) 465-478
18. Notarangelo L., Casanova J.L., Fischer A., Puck J., Rosen F., Seger R., et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 114 (2004) 677-687
19. Goldstein D.B., and Cavalleri G.L. Genomics: understanding human diversity. Nature 437 (2005) 1241-1242
20. Hawn T.R., Verbon A., Lettinga K.D., Zhao L.P., Li S.S., Laws R.J., et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. J Exp Med 198 (2003) 1563-1572
21. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39 (2007) 523-528
22. Martinez F.D. CD14, endotoxin, and asthma risk: actions and interactions. Proc Am Thorac Soc 4 (2007) 221-225
23. Simpson A., John S.L., Jury F., Niven R., Woodcock A., Ollier W.E., et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med 174 (2006) 386-392
24. Nejentsev S., Thye T., Szeszko J.S., Stevens H., Balabanova Y., Chinbuah A.M., et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet 40 (2008) 261-262 author reply 262-3
25. Chen G., Shaw M.H., Kim Y.-G., and Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4 (2009) 365-398
26. Benko S., Philpott D.J., and Girardin S.E. The microbial and danger signals that activate Nod-like receptors. Cytokine 43 (2008) 368-373
27. Martinon F., Mayor A., and Tschopp Jr. The inflammasomes: guardians of the body. Annu Rev Immunol 27 (2009) 229-265
28. Ting J.P.Y., Lovering R.C., Alnemri E.S., Bertin J., Boss J.M., Davis B.K., et al. The NLR gene family: a standard nomenclature. Immunity 28 (2008) 285-287
29. Miao E.A., Andersen-Nissen E., Warren S.E., and Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol 29 (2007) 275-288
30. Franchi L., Eigenbrod T., Munoz-Planillo R., and Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10 (2009) 241-247
31. Masters S.L., Simon A., Aksentijevich I., and Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27 (2009) 621-668
32. Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46 (2002) 3340-3348
33. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
34. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355 (2006) 581-592
35. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
36. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
37. Noguchi E., Homma Y., Kang X., Netea M.G., and Ma X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10 (2009) 471-479
38. Strober W., Kitani A., Fuss I., Asano N., and Watanabe T. The molecular basis of NOD2 susceptibility mutations in Crohn's disease. Mucosal Immunol 1 suppl 1 (2008) S5-S9
39. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38 (2008) 2085-2089
40. Li H., Willingham S.B., Ting J.P., and Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181 (2008) 17-21
41. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
42. Horner A.A., Redecke V., and Raz E. Toll-like receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 4 (2004) 555-561
43. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 161 (1998) 7054-7062
44. Fanucchi M.V., Schelegle E.S., Baker G.L., Evans M.J., McDonald R.J., Gershwin L.J., et al. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med 170 (2004) 1153-1157
45. Gauvreau G.M., Hessel E.M., Boulet L.P., Coffman R.L., and O'Byrne P.M. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 174 (2006) 15-20
46. Casale T.B., Kessler J., and Romero F.A. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 97 (2006) 454-456
47. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T., et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 167 (2001) 66-74
48. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 113 (2004) 235-241
49. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006) 1445-1455
50. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
51. Casella C.R., and Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65 (2008) 3231-3240
52. Schwarz T.F. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7 (2008) 1465-1473
53. Kong N.C.T., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 73 (2007) 856-862